Cannabidivarin for Use in the Treatment of Neuropathic Pain

(19) TZZ ZZ_T

(11) EP 2 709 604 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/05 (2006.01) A61K 31/185 (2006.01) 01.02.2017 Bulletin 2017/05 A61K 31/352 (2006.01) A61P 25/02 (2006.01)

(21) Application number: 12722495.4 (86) International application number: PCT/GB2012/051129 (22) Date of filing: 18.05.2012 (87) International publication number: WO 2012/160358 (29.11.2012 Gazette 2012/48)

(54) CANNABIDIVARIN FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN CANNABIDIVARIN ZUR VERWENDUNG BEI DER BEHANDLUNG VON NEUROPATHISCHEM SCHMERZ CANNABIDIVARINE DESTINÉE À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE

(84) Designated Contracting States: •GUY,Geoffrey AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Salisbury SP4 0JQ (GB) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • STOTT, Colin PL PT RO RS SE SI SK SM TR Salisbury SP4 0JQ (GB) • KIKUCHI, Tetsuro (30) Priority: 20.05.2011 GB 201108506 Osaka-shi Osaka 5410045 (JP) (43) Date of publication of application: 26.03.2014 Bulletin 2014/13 (74) Representative: Wells, Andrew et al HGF Limited (73) Proprietor: GW Pharma Limited 4th Floor, Merchant Exchange Histon 17-19 Whitworth Street West Cambridge CB24 9BZ (GB) Manchester M1 5WG (GB)

(72) Inventors: (56) References cited: • MAIONE, Sabatino GB-A- 2 381 194 GB-A- 2 450 493 I-80138 Naples (IT) US-A1- 2004 192 760 • ROSSI, Francesco I-80138 Naples (IT)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 709 604 B1

Printed by Jouve, 75001 PARIS (FR) EP 2 709 604 B1

Description

[0001] The present invention relates to cannabidivarin (CBDV) for use in the treatment of neuropathic pain.

5 BACKGROUND TO THE INVENTION

[0002] Pain is one of the most common reasons for a patient to seek medical care and in consequence, pain results in a tremendous number of lost work days per year. There are three general classes of pain: nociceptive pain, neuropathic pain, and psychogenic pain. Figure 1 illustrates the relationship between different types of pain and conditions affected, 10 such as allodynia and multiple sclerosis. [0003] In nociceptive pain, the stimulation of the sensory nerve endings called nociceptors cause the sensation of pain. Such pain often occurs after injury or surgery. The pain signals are transmitted by the nociceptors to the brain. Often the pain is localised, constant and has an aching or throbbing quality. Once the damage to the tissue heals, the pain usually resolves. Treatment with opioids often resolves nociceptive pain. 15 [0004] Psychogenic pain is a pain disorder that is associated with psychological factors. Some types of mental or emotional problems can cause pain. They can also increase or prolong pain. Headaches, muscle pains, back pain, and stomach pains are some of the most common types of psychogenic pain. People with this pain disorder actually have real pain. The diagnosis is made when all physical causes of pain are ruled out. [0005] Neuropathic pain is the result of an injury or malfunction of the peripheral or the central nervous system. The 20 pain may be triggered by an injury but not necessarily by an injury of the nervous system itself. Neuropathic pain is frequently chronic and is often refractory to treatment with opioids. [0006] Neuropathic pain is caused by abnormalities in the nerves, spinal cord or brain and is a chronic type of non- malignant pain with an estimated prevalence of over 1% of the population. Optimising pain relief in these patients is crucial in helping a patient regain control of his or her life. 25 [0007] The most common cause of neuropathic pain is injury or dysfunction of nerves. Injury or dysfunction of peripheral nerves or nerves descending from the spinal cord results in disinhibition of nerve impulses at the spinal cord which in consequence results in pain. Neuropathic pain can also be centrally mediated, rather than peripheral, in conditions such as spinal cord injury and multiple sclerosis. [0008] Neuropathic pain can therefore be sub-divided into two further classes; peripheral neuropathic pain and central 30 neuropathic pain depending on whether the peripheral or central nervous system is affected. [0009] Patients with peripheral neuropathic pain often experience pain which feels like a burning or electrical pain, whereas others describe their pain as feeling like extreme cold or pins and needles. The pain may be worsened by activity or by wearing clothes over the affected area. The pain may also follow a daily pattern, which may mean it is worse at certain times of the day. 35 [0010] Allodynia is a type of peripheral neuropathic pain. This is a painful response to a typically non-painful stimulus, for example brushing the affected area with a fingertip. The pain tends to increase with repeated stimulation and may spread from the affected area. Allodynic pain can be evoked in response to chemical, thermal (cold or heat) or mechanical low or high intensity stimuli applied either statically or dynamically to skin, joints, bone, muscle or viscera. It is thought that the presence of allodynic pain is a more suitable means of grouping patients suffering from peripheral neuropathic 40 pain than by the specific disease that led to the neuropathic pain. [0011] It is clear that patients who suffer from neuropathic pain can have their quality of life greatly affected by it. The pain can interfere with work and social activities as well as with the amount and quality of sleep that a patient experiences. A successful treatment for the relief of neuropathic pain should improve both the amount of pain that the patient is experiencing as well as improving the patient’s quality of life. 45 [0012] The use of pharmaceutical medicaments is the most common treatment for neuropathic pain. Analgesics, antidepressants and anticonvulsants are the drug classes generally in use. The drug carbamezepine, which is an anti- convulsant, is currently the only FDA approved drug which has an indication for neuropathic pain. It has been suggested in post-marketing studies that there is a five- to eight-fold increase in the risk of blood dyscrasias in patients taking carbamezepine. In 7% of patients there has been shown to be a 25% decrease in their white blood cell count. 50 [0013] The use of cannabis as a medicine has long been known and during the 19 th Century, preparations of cannabis were recommended as a hypnotic sedative which were useful for the treatment of hysteria, delirium, epilepsy, nervous insomnia, migraine, pain and dysmenorrhoea. [0014] Until recent times the administration of cannabis to a patient could only be achieved by preparation of cannabis by decoction which could then be swallowed, or by the patient inhaling the vapours of cannabis by smoking the dried 55 plant material. Recent methods have sought to find new ways to deliver cannabinoids to a patient including those which bypass the stomach and the associated first pass effect of the liver which can remove up to 90% of the active ingested dose and avoid the patient having to inhale unhealthy tars and associated carcinogens into their lungs. [0015] Formulations containing specific, defined ratios of cannabinoids may be formulated from pure, synthetic or

2 EP 2 709 604 B1

isolated cannabinoids or from extracts derived from the cannabis plant in combination with pharmaceutical carriers and excipients. [0016] Cannabinoids are a group of chemicals known to activate cannabinoid receptors in cells. Phytocannabinoids are the cannabinoids derived from cannabis plants. Endocannabinoids are endogenous cannabinoids found in humans 5 and other animals. The phytocannabinoids can be isolated from plants or produced synthetically. When isolating the phytocannabinoids from plants they can be purified to the extent that all of the other naturally occurring compounds, such as, other minor cannabinoids and plant molecules such as terpenes are removed. This purification results in a purity of greater than 99% (w/w) of the target cannabinoid. [0017] It has been shown previously that the cannabinoid cannabidiol (CBD) administered as a purified compound 10 can partially relieve neuropathic pain (Costa et al., 2004). This was shown using the neuropathic pain model of chronic constriction injury of the rat sciatic nerve and testing the effectiveness of the test article with thermal and mechanical hyperalgesia and mechanical allodynia. These animal models are used to predict the effectiveness of a test compound on neuropathic pain. [0018] More recently the applicant has shown in their granted UK patent, GB2439393, that a plant extract comprising 15 a defined ratio of CBD to THC is more effective at treating peripheral neuropathic pain than the purified components alone. The ratio of CBD to THC which is effective is between 20:1 to 28:1. [0019] The patent application PCT/GB2006/004063 describes the use of an extract of cannabis wherein the THC to CBD ratio is about 1:1. The extract was found to be beneficial in the treatment of peripheral neuropathic pain that is characterised by post-herpetic neuralgia. 20 [0020] The patent application GB 2,450,493 describes that the cannabinoid cannabigerol (CBG) may be used to treat neuropathic pain. [0021] The patent applications US 2004/192760 and GB 2,381,194 both disclose a pharmaceutical formulation which comprises an equal amount of CBDV and THCV. This formulation is suggested to be of use in the treatment of neuropathic pain. 25 [0022] Neuropathic pain is often associated with a diverse and complex set of pain stimuli and as such is difficult to treat effectively as the response to treatment is unpredictable. [0023] Surprisingly, the applicants have found that administration of the cannabinoids cannabigerol (CBG), cannabi- chromene (CBC), cannabidivarin (CBDV) and tetrahydrocannabivarin (THCV) are effective in the treatment of an animal model of neuropathic pain. Since neuropathic pain appears to be refractory to conventional analgesic treatment, such 30 as opiates and non-steroidal anti-inflammatory drugs, the animal studies described herein represents an important finding for clinical settings.

BRIEF SUMMARY OF THE DISCLOSURE

35 [0024] In accordance with a first aspect of the present invention there is cannabidivarin (CBDV) for use in the treatment of neuropathic pain. [0025] Preferably the neuropathic pain is peripheral neuropathic pain, more preferably the peripheral neuropathic pain is allodynia. [0026] Preferably CBDV is present in a dose effective to relieve neuropathic pain. 40 [0027] A low dose of CBDV is defined as an effective human daily dose of CBDV of below 10 mg and a high dose of CBDV is defined as an effective human daily dose of CBDV of 50 mg or above. An intermediate dose is defined as being between 10 mg and 50 mg. [0028] Preferably the effective human daily dose of CBDV is between 5 mg and 100 mg. More preferably the effective human daily dose of CBDV is between10 mg and 50 mg. More preferably still the effective human daily dose of CBDV 45 is between 12 mg and 24 mg. [0029] Preferably the CBDV is packaged for use for an extended treatment period. An extended period will be more preferable, more preferably more than 3 days, more preferably still the extended treatment period is at least 7 days. [0030] In a further embodiment of the present invention the one or more of phytocannabinoids are used in combination with one or more other currently approved non-cannabinoid medicinal substances used in the treatment of neuropathic 50 pain. These medicinal substances include for example analgesics, antidepressants, and anticonvulsants.

BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, 55 in which:

Figure 1 shows the different types of pain that exist;

3 EP 2 709 604 B1

Figure 2 shows the effects of treatment with CBC (2.5 & 5mg/kg, i.p.) on mechanical withdrawal threshold in SNI mice;

Figure 3 shows the effects of treatment with CBC (2.5 & 5mg/kg, i.p.) on thermal withdrawal latency in SNI mice;

5 Figure 4 shows the effects of treatment with CBG (2.5 & 5mg/kg, i.p.) on mechanical withdrawal threshold in SNI mice;

Figure 5 shows the effects of treatment with CBG (2.5 & 5mg/kg, i.p.) on thermal withdrawal latency in SNI mice;

Figure 6 shows the effects of treatment with CBDV (2.5 & 5mg/kg, i.p.) on mechanical withdrawal threshold in SNI 10 mice;

Figure 7 shows the effects of treatment with CBDV (2.5 & 5mg/kg, i.p.) on thermal withdrawal latency in SNI mice;

Figure 8 shows the effects of treatment with THCV (2.5 & 5mg/kg, i.p.) on mechanical withdrawal threshold in SNI 15 mice;

Figure 9 shows the effects of treatment with THCV (2.5 & 5mg/kg, i.p.) on thermal withdrawal latency in SNI mice;

Figure10 shows the effects of treatmentCBD (2.5 &5mg/kg, i.p.) on mechanical withdrawal thresholdin SNI mice;and 20 Figure 11 shows the effects of treatment CBD (2.5 & 5mg/kg, i.p.) on thermal withdrawal latency in SNI mice.

Figures 10 and 11 are included as comparative data given that the use of CBD in neuropathic pain is known.

25 DETAILED DESCRIPTION

[0032] Peripheral neuropathic pain is produced by multiple etiological factors that initiate a number of diverse mech- anismsat differentsites andin different diseasestates. Spared nerve injury (SNI)consists of partialligation and transacti on of the sciatic nerve which evolves in neuropathic pain whose typical manifestations are represented by thermal hyper- 30 algesia and tactile allodynia. [0033] Chronic pain symptoms are measured through changes in thermoceptive responses (which is indicative of thermal hyperalgesia) using Plantar Test Apparatus (Ugo Basile, Varese, Italy) and in mechanical paw withdrawal threshold (which is indicative of mechanical allodynia) by a Dynamic Plantar Aesthesiometer (Ugo Basile, Varese, Italy). Nociceptive responses were measured before and after surgery in groups of mice differently treated (vehicle or drugs 35 different combinations). [0034] The Example below details the results obtained using four different cannabinoids which have not previously been demonstrated as having the ability to reduce neuropathic pain, namely: CBG, CBC, CBDV, and THCV. The cannabinoids were compared to the cannabinoid CBD which has previously been demonstrated to be useful in the treatment of neuropathic pain. 40 [0035] Data relating to cannabinoids other than CBDV do not form part of the invention and are included for comparison only.

EXAMPLE 1: THE EFFECTS OF CANNABINOIDS IN TWO ANIMAL MODELS OF NEUROPATHIC PAIN

45 Materials and Methods

[0036] The cannabinoids tested were CBG, CBC, CBDV, and THCV. In addition the cannabinoid CBD was used as this cannabinoid has previously demonstrated positive results in the animal models of neuropathic pain used in this example. The cannabinoids were prepared from whole plant extracts of cannabis plants which had been purified. The 50 cannabinoids were dissolved in ringer/ 0.5% dimethyl sulfoxide (DMSO), for intraperitoneal (i.p.) administration. [0037] Male CD-1 mice (35-40 g) were housed, 3 per cage, under controlled illumination (12:12 h light : dark cycle; light on 06.00 h) and environmental conditions (room temperature 20-22° C, humidity 55-60%) for at least 1 week before the commencement of experiments. Mouse chow and tap water were available ad libitum. The experimental procedures were approved by the Ethic Committee of the Second University of Naples. Animal care was in compliance with the 55 IASP and European Community (E.C. L358/1 18/12/86) guidelines on the use and protection of animals in experimental research. All efforts were made to minimize animal suffering and to reduce the number of animals used. [0038] Behavioural testing was performed before surgery to establish a baseline for comparison with post-surgical values. Mononeuropathy was induced according to the method of Bourquin and Decosterd (2006).

4 EP 2 709 604 B1

[0039] Mice were anaesthetized with sodium pentobarbital (60 mg/kg i.p.). The right hindlimb was immobilized in a lateral position and slightly elevated. Incision was made at mid-thigh level using the femur as a landmark. The sciatic nerve was exposed at mid-thigh level distal to the trifurcation and freed of connective tissue; the three peripheral branches (sural, common peroneal, and tibial nerves) of the sciatic nerve were exposed without stretching nerve structures. 5 [0040] Both tibial and common peroneal nerves were ligated and transacted together. A micro-surgical forceps with curved tips was delicately placed below the tibial and common peroneal nerves to slide the thread (5.0 silk, Ethicon, Johnson, and Johnson Intl, Brussels, Belgium) around the nerves. A tight ligation of both nerves was performed. The sural nerve was carefully preserved by avoiding any nerve stretch or nerve contact with surgical tools. Muscle and skin were closed in two distinct layers with silk 5.0 sutures. 10 [0041] Intense, reproducible and long-lasting thermal hyperalgesia and mechanical allodynia-like behaviors are meas- urable in the non-injured sural nerve skin territory. The SNI model offers the advantage of a distinct anatomical distribution with an absence of co-mingling of injured and non-injured nerve fibers distal to the lesion such as the injured and non- injured nerves and territories can be readily identified and manipulated for further analysis (i.e. behavioral assessment). [0042] The sham procedure consisted of the same surgery without ligation and transection of the nerves. 15 [0043] The groups of mice were divided as follows, each cannabinoid tested has its own group of mice:

i) Naïve control mice (n = 8); ii) Sham-operated mice treated with vehicle (n = 8); iii) Sham-operated mice treated with cannabinoid (n = 8); 20 iv) SNI mice treated with vehicle (n = 8); v) SNI mice treated with cannabinoid (n = 8).

[0044] The cannabinoids were dosed daily for 14 days. Doses for all cannabinoids tested were: 2.5 and 5.0 mg/Kg. Vehicle solution was 0.5% DMSO in ringer solution. 25 Nociceptive behaviour

[0045] Mechanical allodynia was measured by using Dynamic Plantar Anesthesiometer (Ugo Basile, Varese, Italy). Mice were allowed to move freely in one of the two compartments of the enclosure positioned on the metal mesh surface. 30 Mice were adapted to the testing environment before any measurements were taken. After that, the mechanical stimulus was delivered to the plantar surface of the hindpaw of the mouse from below the floor of the test chamber by an automated testing device. A steel rod (2 mm) was pushed with electronical ascending force (0-30 g in 10 sec). When the animal withdrew its hindpaw, the mechanical stimulus was automatically withdrawn and the force recorded to the nearest 0.1 g. [0046] Thermal hyperalgesia was evaluated by using a Plantar Test Apparatus (Ugo Basile, Varese, Italy). On the day 35 of the experiment each animal was placed in a plastic cage (22cm x 17cm x 14cm; length x width x height) with a glass floor. After a 60 min habituation period, the plantar surface of the hind paw was exposed to a beam of radiant heat through the glass floor. The radiant heat source consisted of an infrared bulb (Osram halogen-bellaphot bulb; 8 V, 50 W). A photoelectric cell detected light reflected from the paw and turned off the lamp when paw movement interrupted the reflected light. The paw withdrawal latency was automatically displayed to the nearest 0.1 sec; the cut-off time was 40 20 sec in order to prevent tissue damage. [0047] Nociceptive responses for thermal and mechanical sensitivity were expressed as thermal paw withdrawal latency (PWL) in seconds and mechanical paw withdrawal threshold (PWT) in grams. [0048] Each mouse served as its own control, the responses being measured both before and after surgical procedures. PWL and PWT were quantified by an observer blinded to the treatment. 45 Statistical analysis

[0049] Behavioural and molecular data were shown as means 6 S.E.M. ANOVA, followed by Student-Neuman-Keuls post hoc test, was used to determine the statistical significance among groups. P<0.01 was considered statistically 50 significant.

Results

Mechanical Withdrawal Threshold 55 [0050] Figures 2, 4, 6, 8 and 10 demonstrate the mechanical withdrawal threshold data obtained for the cannabinoids tested (CBC, CBG, CBDV, THCV and CBD (comparator) respectively). The bar charts illustrate the amount of weight in grams required to make the animal withdraw its hindpaw. As can be seen all of the cannabinoids tested were able

5 EP 2 709 604 B1

allow the animals with the SNI to increase the amount of weight applied before it withdrew its paw, and as such were able to prevent, at varying degrees, mechanical allodynia at 3, 7 and 14 days after spared nerve injury. The analgesic effects were dose-dependent as greater effects were observed in animals receiving the 5.0 mg/kg dose of cannabinoid.

5 Thermal Withdrawal Latency

[0051] Figures 3, 5, 7, 9 and 11 demonstrate the thermal withdrawal latency data obtained for the cannabinoids tested (CBC, CBG, CBDV, THCV and CBD (comparator) respectively). The bar charts illustrate the amount of time in seconds before the animal withdrew its paw from the heat source. As can be seen all of the cannabinoids tested were able to 10 allow the animals with the SNI to increase the amount of time before it withdrew its paw, and as such were able to prevent, at varying degree, thermal hyperalgesia at 3, 7 and 14 days after spared nerve injury. [0052] For the cannabinoids CBC, CBG, THCV and CBD the effects do not appear to be dose-dependent as animals treated with 2.5 and 5 mg/kg had similar withdrawal latencies, or are reaching maximum effect at a lower dose [0053] However for the cannabinoid CBDV dose-dependent effects were observed. Animals treated with the 2.5mg/kg 15 dose had similar withdrawal latencies to the control group at day 3 post nerve injury. However, animals treated with the 5.0 mg/kg dose were able to increase the amount of time before the paw was withdrawn from the heat source, to the extent that at 14 days post nerve injury, with this group had similar withdrawal latencies to the naive and sham control animals.

20 COMBINATION OF DATA

[0054] In order to ascertain the different degrees of effectiveness of the cannabinoids tested the tables below describe the data generated in this example in tabular form. [0055] Table 1 below describes the effects of the treatment with cannabinoids on mechanical withdrawal threshold in 25 mice.

Table 1: Mechanical withdrawal threshold - combined data TEST ARTICLE MECHANICAL WITHDRAWAL THRESHOLD (g)

30 DAY 3 DAY 7 DAY 14

Naive 9.5 9.5 9.5 Sham / vehicle 8.8 8.6 9.0 35 SNI / vehicle 3.2 3.0 3.1

SNI / CBC (2.5 mg/kg) 2.4 4.5 5.0

40 SNI / CBG (2.5 mg/kg) 3.4 6.1 7.8 SNI / CBDV (2.5 mg/kg) 6.8 7.0 7.8 SNI / THCV (2.5 mg/kg) 3.0 6.2 7.5 SNI / CBD (2.5 mg/kg) 2.2 4.8 5.2 45

SNI / CBC (5 mg/kg) 5.1 9.7 5.2 SNI / CBG (5 mg/kg) 6.0 6.1 7.8

50 SNI / CBDV (5 mg/kg) 6.7 6.6 7.7 SNI / THCV (5 mg/kg) 3.2 8.5 9.8 SNI / CBD (5 mg/kg) 5.0 8.6 5.3

55 [0056] As can be seen from Table 1 above most of the cannabinoids at the 2.5 mg/kg dose show a slight increase in the amount of weight applied before the animal withdraws its paw, this effect appears to increase over time from day 3 to day 7 to day 14. With the 2.5 mg/kg dose of the cannabinoid CBDV there is however a dramatic increase in the

6 EP 2 709 604 B1

mechanical withdrawal latency even at the day 3 time point inferring that this cannabinoid is able to be effective quickly, whereas the other cannabinoids take a week or more to become effective. [0057] At the 5.0 mg/kg dose all of the cannabinoids except THCV were able to increase the amount of weight applied before the animal withdrew its paw. The cannabinoids CBC and CBD showed a large increase at day 7; however this 5 latency decreased again at the 14 day time point. [0058] Surprisingly these data demonstrate that at both of the doses tested the cannabinoid CBDV was shown to have the highest mechanical withdrawal latency of all the cannabinoids. The cannabinoids CBG and THCV also showed good efficacy as they had reasonably high mechanical withdrawal latencies. However the cannabinoids CBC and CBD were shown to be relatively ineffective in the treatment of neuropathic pain at this dose. This finding demonstrates that the 10 cannabinoids CBDV, THCV and CBG are superior to CBD in their ability to treat the neuropathic pain brought about by the animal model used in this experiment. [0059] Table 2 below describes the effects of the treatment with cannabinoids on thermal withdrawal latency in mice.

Table 2: Thermal withdrawal latency - combined data 15 TEST ARTICLE THERMAL WITHDRAWAL LATENCY (s) DAY 3 DAY 7 DAY 14

20 Naive 10.0 10.0 10.0 Sham / vehicle 9.7 9.7 9.7 SNI / vehicle 3.8 3.5 3.9

25 SNI / CBC (2.5 mg/kg) 3.7 4.8 5.2 SNI / CBG (2.5 mg/kg) 5.5 5.4 7.0 SNI / CBDV (2.5 mg/kg) 3.8 6.4 6.5

30 SNI / THCV (2.5 mg/kg) 3.8 9.8 7.6 SNI / CBD (2.5 mg/kg) 3.5 4.2 5.6

SNI / CBC (5 mg/kg) 6.0 7.0 7.2 35 SNI / CBG (5 mg/kg) 7.8 7.6 7.5 SNI / CBDV (5 mg/kg) 4.0 7.2 11.0 SNI / THCV (5 mg/kg) 3.9 10.5 11.9

40 SNI / CBD (5 mg/kg) 5.8 7.0 7.5

[0060] As can be seen from Table 2 most of the cannabinoids at the 2.5 mg/kg dose shows a slight increase in the amount of time before the animal withdraws its paw this effect appears to increase over time from day 3 to day 7 to day 14. At the day 3 time point only the 2.5 mg/kg dose CBG appears to have any increase in the amount of thermal withdrawal 45 latency. For the cannabinoid THCV there appears to be a large increase at the day 7 time point which then decreases after a further 7 days. [0061] At the 5.0 mg/kg dose the cannabinoids CBC, CBG and CBD were able to increase the amount of time before the animal withdrew its paw at the three day time point. After a week of treatment with the cannabinoids however all test groups showed an increase in the thermal withdrawal latency. THCV and CBDV both showed a large increase after 14 50 days of treatment inferring that the effectiveness of the cannabinoids builds up over time. [0062] Surprisingly these data demonstrate that at the 2.5 mg/kg dose the cannabinoid CBG was shown to have the highest thermal withdrawal latency of all the cannabinoids. The cannabinoids CBDV and THCV also showed good efficacy as they had reasonably high mechanical withdrawal latencies. However the cannabinoids CBC and CBD were shown to be relatively ineffective in the treatment of neuropathic pain at this dose. At the 5.0 mg/kg dose both the 55 cannabinoids CBDV and THCV were shown to be most effective. This finding demonstrates that the cannabinoids CBDV, THCV and CBG are superior to CBD in their ability to treat the neuropathic pain brought about by the animal model used in this experiment.

7 EP 2 709 604 B1

[0063] The human dose equivalent (HED) can be estimated using the following formula:

[0064] The Km for a mouse is 3 and for a rat the value is 6 and the K m for a human is 37. [0065] Thus, for a human of approximately 60 kg a 2.5 mg/kg dose in a mouse would equate to a human daily dose 10 of about 12 mg.

Claims

15 1. Cannabidivarin (CBDV) for use in the treatment of neuropathic pain.

2. CBDV, for use according to claim 1 wherein the neuropathic pain is peripheral neuropathic pain.

3. CBD, for use according to claim 2, wherein the peripheral neuropathic pain is allodynia. 20 4. CBDV for use according to any of the preceding claims, wherein the CBDV is present in an effective human daily dose of between 5 mg and 100 mg.

5. CBDV for use according to claim 4, wherein the CBDV is present in an effective human daily dose of between 10 25 mg and 50 mg.

6. CBDV for use according to any of the preceding claims, wherein the CBDV is packaged for use for an extended treatment period.

30 7. CBDV for use according to claim 6, wherein the extended treatment period is at least 7 days.

8. CBDV for use according to any of the preceding claims, in combination with one or more other non-cannabinoid medicinal substances.

35 Patentansprüche

1. Cannabidivarin (CBDV) zur Verwendung in der Behandlung neuropathischer Schmerzen.

40 2. CBDV zur Verwendung nach Anspruch 1, wobei die neuropathischen Schmerzen periphere neuropathische Schmer- zen sind.

3. CBDV zur Verwendung nach Anspruch 2, wobei es sich bei den peripheren neuropathischen Schmerzen um Allo- dynie handelt. 45 4. CBDV zur Verwendung nach einem der vorstehenden Ansprüche, wobei das CBDV in einer wirksamen Tagesdosis für einen Menschen in Höhe von 5 mg bis 100 mg vorhanden ist.

5. CBDV zur Verwendung nach Anspruch 4, wobei das CBDV in einer wirksamen Tagesdosis für einen Menschen in 50 Höhe von 10 mg bis 50 mg vorhanden ist.

6. CBDV zur Verwendung nach einem der vorstehenden Ansprüche, wobei das CBDV zur Verwendung über einen ausgedehnten Behandlungszeitraum verpackt ist.

55 7. CBDV zur Verwendung nach Anspruch 6, wobei der ausgedehnte Behandlungszeitraum wenigstens 7 Tage beträgt.

8. CBDV zur Verwendung nach einem der vorstehenden Ansprüche in Kombination mit einer oder mehreren anderen medizinischen Substanzen, die nicht Cannabinoide sind.

8 EP 2 709 604 B1

Revendications

1. Cannabidivarine (CBDV) destinée à être utilisée dans le traitement d’une douleur neuropathique.

5 2. CBDV destinée à être utilisée selon la revendication 1, la douleur neuropathique étant une douleur neuropathique périphérique.

3. CBD destinée à être utilisée selon la revendication 2, la douleur neuropathique périphérique étant une allodynie.

10 4. CBDV destinée à être utilisée selon l’une quelconque des revendications précédentes, la CBDV étant présente dans une dose quotidienne humaine efficace comprise entre 5 mg et 100 mg.

5. CBDV destinée à être utilisée selon la revendication 4, la CBDV étant présente dans une dose quotidienne humaine efficace comprise entre 10 mg et 50 mg. 15 6. CBDV destinée à être utilisée selon l’une quelconque des revendications précédentes, la CBDV étant emballée pour être utilisée pendant une durée de traitement prolongée.

7. CBDV destinée à être utilisée selon la revendication 6, la durée de traitement prolongée étant d’au moins 7 jours. 20 8. CBDV destinée à être utilisée selon l’une quelconque des revendications précédentes, en association avec une ou plusieurs autres substances médicamenteuses non cannabinoïdes.

9 EP 2 709 604 B1

10 EP 2 709 604 B1

11 EP 2 709 604 B1

12 EP 2 709 604 B1

13 EP 2 709 604 B1

14 EP 2 709 604 B1

15 EP 2 709 604 B1

16 EP 2 709 604 B1

17 EP 2 709 604 B1

18 EP 2 709 604 B1

19 EP 2 709 604 B1

20 EP 2 709 604 B1

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

• GB 2439393 A [0018] • US 2004192760 A [0021] • GB 2006004063 W [0019] • GB 2381194 A [0021] • GB 2450493 A [0020]